Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR439459 and Cemiplimab in Advanced Solid Tumors
NCT04729725Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAR439459 in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Clinical Benefit Rate at 12 weeks. Started Feb 2021; status: terminated.
02
Drugs
SAR439459
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04729725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729725.